Table 1 Patient demographics

From: Brain serotonin synthesis capacity in obsessive-compulsive disorder: effects of cognitive behavioral therapy and sertraline

Characteristic

CBT (n = 8)

SSRI (n = 8)

Age, y

Mean (SD)

33.7 (9.5)

33.4 (8.5)

Range

23–53

18–45

Responders/partial responders

4/8

6/8

Early-onset OCD (≤10 y), No.

5

5

Predominant compulsion, No.

Washing

4

4

Checking

4

4

Lifetime history of MDE (2° to OCD symptoms), No.

2

3

Past substance abuse, No.

0

0

 

Pre

Post

Pre

Post

Y-BOCS score, mean (SD)

23 (4.4)

15.8 (7.5)

23.6 (5.6)

14.7 (8.2)

BDI score, mean (SD)

9.8 (4.5)

6.9 (6.0)

14.1 (11.2)

7.6 (9.5)

Plasma free tryptophan, mean (SD), nmol/La

10.3 (2.6)

8.4 (1.4)

9.8 (1.7)

9.3 (2.1)

Global K*, mean (SD), mL/g/mina

5.1 (1.3)

6.1 (1.5)

5.8 (1.3)

6.07 (2.0)

Intravenously injected, mean (SD), mCia

9.3 (1.1)

9.6 (0.7)

9.6 (0.8)

9.7 (0.4)

  1. Responders/partial responders demonstrated a >25% decrease in Y-BOCS score
  2. OCD obsessive-compulsive disorder, CBT cognitive behavioral therapy, SSRI selective serotonin re-uptake inhibitor, MDE major depressive episode, Y-BOCS Yale-Brown Obsessive Compulsive Scale, BDI Beck Depression Inventory, No. number
  3. aData not included for one patient treated with CBT